Literature DB >> 3707106

Reduction of oral flora with rifampin in healthy volunteers.

P C Appelbaum, S K Spangler, C R Potter, F R Sattler.   

Abstract

The effect of a short course of rifampin on the oral microflora was evaluated in 17 healthy volunteers. Salivary specimens were collected before and after two 600-mg doses of rifampin administered 6 h apart. Salivary bacteria were identified to species, and total quantitative colony counts were determined for each isolate. For all 17 subjects, treatment with rifampin led to a reduction in total bacterial colony counts; the mean inhibitory activity was 85.8% (range, 48.3 to 99.8%). Both aerobic and anaerobic bacteria were inhibited in every case: 45.5 to 99.8% for aerobic bacteria, mean inhibitory activity of 85.8%; 40.9 to 100% inhibition for anaerobic bacteria, mean inhibitory activity of 87.6%. However, total counts were reduced by greater than or equal to 2 logarithms in only 18% of individuals; for aerobes, in 29%; and for anaerobes, in 41%. All classes of bacteria were inhibited, with mean inhibitory activities ranging from 8.4 to 99.9%. However, only streptococci, Haemophilus spp., Bacteroides spp., and aerobic and anaerobic gram-positive nonsporeforming rods were reduced in counts close to 2 logarithms after treatment with rifampin. Clinical studies are needed to clarify the significance of these in vitro data and to delineate a possible role for rifampin in preoperative prophylaxis of patients undergoing head and neck cancer surgery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707106      PMCID: PMC180444          DOI: 10.1128/AAC.29.4.576

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The role of prophylactic antibiotic therapy in control of staphylococcal infections following cancer surgery.

Authors:  A S KETCHAM; J H BLOCH; D T CRAWFORD; J E LIEBERMAN; R R SMITH
Journal:  Surg Gynecol Obstet       Date:  1962-03

2.  Infection surveillance: identifying the problems and the high-risk patient.

Authors:  P Cruse
Journal:  South Med J       Date:  1977-10       Impact factor: 0.954

3.  Prophylactic antibiotics in oral, pharyngeal and laryngeal surgery for cancer: (a double-blind study).

Authors:  P Dor; J Klastersky
Journal:  Laryngoscope       Date:  1973-12       Impact factor: 3.325

4.  Effect of prophylactic antibiotics in radical head and neck surgery.

Authors:  R L Goode; N Abramson; W E Fee; P Levine
Journal:  Laryngoscope       Date:  1979-04       Impact factor: 3.325

5.  Avoidance of early complications following radical neck dissection.

Authors:  P S Camnitz; W P Biggers; N D Fischer
Journal:  Laryngoscope       Date:  1979-10       Impact factor: 3.325

6.  Prophylactic antibiotics in otolaryngologic surgery: a double-blind study.

Authors:  L T Eschelman; A J Schleuning; R E Brummett
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1971 Mar-Apr

7.  Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease.

Authors:  F Cox; R Trincher; J P Rissing; M Patton; G H McCracken; D M Granoff
Journal:  JAMA       Date:  1981-03-13       Impact factor: 56.272

8.  Antimicrobial prophylaxis for contaminated head and neck surgery.

Authors:  J T Johnson; E N Myers; P B Thearle; B A Sigler; V L Schramm
Journal:  Laryngoscope       Date:  1984-01       Impact factor: 3.325

9.  Chemoprophylaxis for surgery of the head and neck.

Authors:  G D Becker
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1981 May-Jun

10.  Wound infection following laryngectomy. The effect of topical ampicillin and carbenicillin.

Authors:  J M Robinson
Journal:  J Laryngol Otol       Date:  1976-05       Impact factor: 1.469

View more
  1 in total

1.  Early specific host response associated with starting effective tuberculosis treatment in an infection controlled placebo controlled mouse study.

Authors:  Alice L den Hertog; Alex F de Vos; Paul R Klatser; Richard M Anthony
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.